As editor-in-chief of *The Journal of Nuclear Medicine* (*JNM*), I have the pleasure each year of working with our associate editors and editorial board to select by anonymous vote the outstanding contributions to the journal for recognition at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging. The *JNM* Editors’ Choice Awards for articles published in the journal in 2022 were chosen from a group of extraordinarily high-quality and innovative submissions. This year, the research and findings of the awardees represent the advances in theranostics, both clinical and preclinical, that are positioning nuclear medicine at the leading edge of cancer treatment.

In the category of Best Clinical Article, the award went to Richard P. Baum, from the Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Germany (currently with Curanosticum Wiesbaden–Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany), and coauthors Christiane Schuchardt, Aviral Singh, Maythinee Chantadisai, Franz C. Robiller, Jingjing Zhang, Dirk Mueller, Alexander Eismant, Frankis Almaguel, Dirk Zboralski, Frank Osterkamp, Aileen Hoehne, Ulrich Reineke, Christiane Smerling, and Harshad R. Kulkarni for “Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radio-nuclide Therapy of Diverse Adenocarcinomas Using $^{177}$Lu-FAP-2286: First-in-Humans Results” (*J Nucl Med.* 2022;63:415–423). This contribution was also named the best overall article in the journal for 2022.

Ronnie C. Mease, from the Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine (Baltimore, MD), and coauthors Choong Mo Kang, Vivek Kumar, Sangeeta Ray Banerjee, Il Minn, Mary Brummet, Kathleen L. Gabrielson, Yutian Feng, Andrew Park, Ana P. Kiess, George Sgouros, Ganesan Vaidyanathan, Michael R. Zalutsky, and Martin G. Pomper were the recipients of the Best Basic Science Article award for “An Improved $^{211}$At-Labeled Agent for PSMA-Targeted α-Therapy” (*J Nucl Med.* 2022;63:259–267).

These and similar efforts ensure that *JNM* remains the international journal of choice for publishing clinical, basic, and translational research in nuclear medicine, molecular imaging, radiopharmaceutical therapy, and theranostics.